spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Tower to bring the temperature of pharmaceutical logistics to CPhI

Tower Cold Chain


Temperature-controlled containers that combine robust, reliable, and reusable benefits for the pharmaceutical supply chain will be showcased on the Tower Cold Chain stand, 91H66, zone ICSE, at this year’s CPhI worldwide, in Frankfurt.

As first-time exhibitors at CPhI, Tower will use the world’s premier event for the pharmaceutical industry, to demonstrate the new passive KTEvolution container – the company’s first manually handleable solution ideal for smaller shipments such as direct-to-patient, clinical trials and last-mile deliveries.

Visitors to the Tower stand will see how the revolutionary KTEvolution offers easy, cost-effective, and compliant transport of pharmaceuticals, life-science and biotech products that require an internal temperature of <-60°c, -20°c, +5°c, or +20°C. Using phase-change technology incorporated with lightweight vacuum insulated panels, the KTE achieves its long-term thermal protection, whilst maintaining Tower’s commitment to sustainability.

“The KTEvolution fills a gap in the cold chain shipping market, with a patent-pending design that strikes the optimum balance between high performance, durability, and optimised weight,” said Niall Balfour, CEO of Tower Cold Chain. “We’re delighted to welcome attendees to our stand to see our cold chain technology up close and witness our customer led innovations.”

The KTEvolution will be exhibited alongside the KT400 Tower Flexi Fit container – one of Tower’s most popular solutions, allowing for a multitude of different pharmaceutical packaging alternatives to be transported safely, simply and easily. Like all containers in the KTM range, the KT400 provides 120+ hour thermal protection without the need for external power nor human intervention during transit.

Tower’s stand will have a distinctly international presence, with members of its APAC, Americas and European teams, all in attendance at CPhI.

“CPhI is widely considered the barometer of the pharmaceutical industry,” concluded Niall. “We’re delighted to be sharing the stage for the first time, with leading manufacturers, 3PLs and airlines, to present our robust, reliable, reusable solutions that make Tower a trusted partner for efficient pharmaceutical logistics worldwide.”
phone +44 118 932 5000
email info@towercoldchain.com
web https://www.towercoldchain.com/
email Unit A, Total Park, Station Road, Theale, Reading, Berkshire RG7 4PN, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA

Stockley Park, UK – 22 July 2022 – Kite, a Gilead Company, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (ALL). If approved, brexucabtagene autoleucel will be the first and only CAR T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival (OS) for this group is only approximately eight months with current standard-of-care treatments.[1],[2]
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement